City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based ...

The approval allows Imfinzi to be used in... Sanofi’s New Hemophilia Drug Qfitlia Gains FDA Approval with Breakthrough Bimonthly Dosing The U.S. Food and Drug Administration (FDA) has approved ...

The approval allows Imfinzi to be used in... Sanofi’s New Hemophilia Drug Qfitlia Gains FDA Approval with Breakthrough Bimonthly Dosing The U.S. Food and Drug Administration (FDA) has approved ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ...

BofA raised the firm’s price target on Alnylam (ALNY) to $328 from $325 and keeps a Buy rating on the shares. The firm updated models in ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May ...

Eligible patients taking Camzyos in the maintenance phase now only require twice-yearly echocardiogram monitoring. The Food and Drug Administration (FDA) has updated the labeling for Camzyos ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In talking with his son about past Easter egg hunts, columnist Joe MacDonald recalls a lesson on finding strength amid adversity.